Welcome to our dedicated page for Recursion Pharmaceuticals SEC filings (Ticker: RXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) provides access to the company’s official regulatory disclosures as a clinical-stage TechBio and biotechnology issuer. These documents offer detailed information about Recursion’s financial condition, governance, capital markets activity and key corporate events related to its Recursion OS platform and drug development programs.
Investors can review current reports on Form 8-K, where Recursion reports material events such as quarterly financial results, leadership transitions, collaboration milestones and equity issuances. Recent 8-K filings describe items including second and third quarter financial results, the appointment of a new Chief Executive Officer and President with the prior CEO becoming Chair of the Board, milestone payments from collaborations, and unregistered sales of equity securities connected to acquisitions and license arrangements.
Through its registration statements and prospectus supplements filed under its automatic shelf registration on Form S-3ASR, Recursion documents offerings and resale registrations for shares issued in connection with agreements such as a master license with Tempus AI, Inc. and a membership interest purchase agreement involving a joint venture for an ENPP1 program. These filings outline the number of shares involved, transaction structure and reliance on exemptions from registration for initial issuances.
Users of this page can also monitor filings related to corporate governance and stockholder matters, such as annual meeting results and advisory votes, as well as information about independent auditor ratification. Together with annual reports on Form 10-K and quarterly reports on Form 10-Q, which are accessible through EDGAR, these filings form a comprehensive record of RXRX’s regulatory history.
Stock Titan enhances this information by pairing real-time EDGAR updates with AI-powered summaries that explain the significance of key filings. This helps readers quickly interpret lengthy documents such as 10-K and 10-Q reports, understand the implications of Form 8-K disclosures, and track any insider-related or equity issuance activity that may be relevant when evaluating Recursion Pharmaceuticals.
Recursion Pharmaceuticals CFO Ben R. Taylor reported a tax-related share disposition. On April 6, 2026, 48,028 shares of Class A Common Stock at $3.11 per share were withheld by the company to cover tax obligations from net settlement of restricted stock units. After this withholding, Taylor directly owns 1,132,290 shares of the company’s Class A Common Stock.
Recursion Pharmaceuticals director Christopher Gibson converted and sold shares of the company’s stock. On April 7, he converted 40,000 shares of Class B Common Stock into 40,000 shares of Class A Common Stock and then sold 40,000 Class A shares at $3.10 per share in an open-market transaction.
The trades were made pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2025. Following these transactions, he directly holds 906,556 shares of Class A Common Stock and 4,443,334 shares of Class B Common Stock, while various family entities no longer show Class B holdings in this filing.
Recursion Pharmaceuticals director Blake Borgeson reported an open-market sale of Class A Common Stock. On this transaction date, he sold 30,000 shares at a price of $3.10 per share. After the sale, he directly held 6,229,863 shares of Class A Common Stock.
The sale was executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted by Borgeson on August 31, 2025, indicating the trade was scheduled in advance rather than timed discretionarily.
Christopher C. Gibson reported proposed and recent resale activity of Class A shares under Form 144. The filer lists multiple proposed sales and shows four Class A dispositions in the past three months: 40,000 shares on 01/20/2026 for $178,800; 40,000 shares on 02/04/2026 for $164,800; 40,000 shares on 02/19/2026 for $138,400; and 40,000 shares on 03/23/2026 for $130,000. The filing also lists a proposed sale of 40,000 Class A "Founders Shares" with a broker designation of Fidelity Brokerage Services LLC.
Blake C. Borgeson filed a Form 144 notice reporting recent and planned sales of Class A common stock. The filing lists 30,000 Class A shares to be sold through Fidelity Brokerage Services on 04/07/2026. It also discloses prior sales of 220,000 shares on 02/03/2026 for $924,000 and 170,000 shares on 03/03/2026 for $588,200.
Dar Zavain reported acquisition or exercise transactions in this Form 4 filing.
RECURSION PHARMACEUTICALS, INC. director Zavain Dar received a grant of 4,902 shares of Class A Common Stock. The shares were issued at no cash cost to him under the company’s Outside Director Compensation Policy and are reported as directly owned. Following this award, he holds 147,231 Class A shares.
Li Dean Y reported acquisition or exercise transactions in this Form 4 filing.
RECURSION PHARMACEUTICALS, INC. director Dean Y. Li received a grant of 3,268 shares of Class A Common Stock at $0.0000 per share. The shares were issued under the company’s Outside Director Compensation Policy, reflecting equity-based compensation rather than an open-market purchase.
Following this grant, Li directly owns 1,244,177 Class A shares. He also has indirect ownership through several entities, including the Dean Y. Li Revocable Trust, the Dean Y. Li GRAT, and the Dean Y. Li 2021 Family Trust, each with separately reported share balances.
Recursion Pharmaceuticals Inc filing: The Vanguard Group amended its Schedule 13G/A to report that it beneficially owns 0 shares of Recursion Pharmaceuticals Inc common stock, representing 0% of the class. The filing explains this follows an internal realignment of The Vanguard Group, Inc., resulting in disaggregated reporting by subsidiaries.
Recursion Pharmaceuticals is changing its top medical leadership. Vicki Goodman, M.D. will become Chief Medical Officer effective April 6, 2026, succeeding David Mauro, M.D., Ph.D., who will stay on as an advisor through May 29, 2026.
The company highlights Dr. Goodman’s more than two decades of oncology drug development experience, including senior roles at biotech and large pharmaceutical companies and prior service as an FDA medical officer. Management emphasizes her expertise in late-stage clinical development and regulatory strategy as Recursion advances its pipeline toward key clinical and regulatory milestones.
Recursion Pharmaceuticals director Christopher Gibson converted and sold shares of the company’s stock. He converted 40,000 shares of Class B Common Stock into 40,000 shares of Class A Common Stock, then sold 40,000 Class A shares at $3.25 per share in an open-market transaction pursuant to a Rule 10b5-1 trading plan. Following these transactions, he holds 906,556 shares of Class A Common Stock and 4,483,334 shares of Class B Common Stock directly.